EP
OPRX icon

Eudaimonia Partners’s OptimizeRx OPRX Stock Holding History

Eudaimonia Partners’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,902
Closed -$123K – 897
2020
Q3 		$123K Hold
5,902
– – 0.03% 367
2020
Q2 		$77K Buy
5,902
+1,400
+31% +$15.2K 0.03% 414
2020
Q1 		$41K Buy
+4,502
New +$42.7K 0.02% 509

Other funds holding OPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Eudaimonia Partners's OPRX Position: Q4 2020 in Review

Eudaimonia Partners sold out of OptimizeRx (OPRX) in Q4 2020, closing a stake of 5,902 shares — an estimated $123K sold.

Eudaimonia Partners first reported a position in OPRX in Q1 2020 and held it in 3 quarters. The position peaked at $123K in Q3 2020. 86 funds tracked by Wall St. Rank hold OPRX as of Q4 2020.

  • Eudaimonia Partners reported no remaining OptimizeRx position as of Q4 2020 after selling out during the quarter.
  • Eudaimonia Partners sold 5,902 OptimizeRx shares in Q4 2020, an estimated $123K.
  • Eudaimonia Partners first reported a position in OptimizeRx in Q1 2020 and held it in 3 quarters.
  • Eudaimonia Partners's OptimizeRx position peaked at $123K in Q3 2020.
  • 86 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2020.

Based on Eudaimonia Partners's 13F filing for Q4 2020, filed 18 Feb 2021.